New hope for seniors with myeloma: tailored drug combo shows promise
NCT ID NCT04151667
First seen Sep 30, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tests a treatment plan that adjusts medications based on how well the cancer responds in adults aged 65 and older with newly diagnosed multiple myeloma. The main goal is to see how many patients achieve a significant reduction or disappearance of cancer signs. The approach uses the drug daratumumab in combination with other therapies, aiming to control the disease while avoiding harsh side effects from standard high-dose chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.